Innovent's Mazdutide Shows Significant Weight Loss & Metabolic Benefits In Chinese Adolescents

Innovent Biologics said a 36‑patient Phase 1b randomized, double‑blind placebo‑controlled trial of mazdutide (IBI362), a GLP‑1/glucagon dual agonist, in Chinese adolescents (12–18) with obesity met its primary endpoint after 12 weeks: BMI fell 8.78% and 10.99% in the 4 mg and 6 mg arms versus 1.73% for placebo, with weight losses of 7.72 kg and 8.65 kg versus 1.42 kg on placebo. The drug produced improvements in waist circumference, blood pressure, lipids, liver enzymes and glycemic control, showed similar pharmacokinetics to adults and was well tolerated with no serious adverse events and only mild–moderate GI effects. With adolescent obesity rising sharply in China and no approved pediatric weight‑loss drugs there, Innovent plans a Phase 3 registrational trial—positioning mazdutide as a potential first approved therapy in a large, unmet market.

Analysis

Innovent Biologics reported that a 36-patient, multicenter, randomized, double-blind, placebo-controlled Phase 1b trial of mazdutide (IBI362) in Chinese adolescents (ages 12–18) with obesity met its primary endpoint after 12 weeks. Subjects randomized to mazdutide 4 mg and 6 mg experienced BMI reductions of 8.78% and 10.99% and weight losses of 7.72 kg and 8.65 kg, respectively, versus 1.73% BMI reduction and 1.42 kg weight loss on placebo, with participants having previously failed diet/exercise impacts (<5% BMI reduction).

Mazdutide produced secondary improvements in waist circumference, blood pressure, blood lipids, liver enzymes and glycemic control, while pharmacokinetic exposure in adolescents was reported as similar to adults. Safety was favorable in this small cohort: all subjects completed the study, no serious adverse events or discontinuations were reported, and the most common adverse events were mild-to-moderate gastrointestinal reactions.

The company plans a Phase 3 registrational trial to pursue approval in a Chinese pediatric population where no weight-loss medications are currently approved and adolescent obesity has risen substantially, indicating a meaningful unmet market. Market sentiment signals attached to the news are moderately positive with a modest market-impact score (0.35), implying commercial interest but material regulatory and confirmatory data risk ahead.

Key Decisions for Investors

• Consider selective exposure to Innovent Biologics to capture potential first-mover advantage in China’s pediatric obesity market, but size allocations conservatively given the small Phase 1b sample and need for Phase 3 confirmation
• Monitor Phase 3 trial design, enrollment timelines, primary endpoints and regulatory interactions in China as the primary near-term catalysts for valuation repricing
• Prioritize safety surveillance and any emerging tolerability signals in larger trials since current safety data are encouraging but limited to 36 patients
• Use the current moderately positive market sentiment as an opportunity to set alerts and reassess positions upon Phase 3 initiation or interim efficacy/safety readouts rather than relying solely on this press release